Skip to Main Content

Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids (PRIMROSE 1)

Conditions

Women's Health | Pregnancy, Childbirth and the Puerperium

Phase III

What is the purpose of this trial?

Brief Summary:

The primary objective of this study is to demonstrate the superior efficacy versus placebo of OBE2109 alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

  • Trial with
    ObsEva SA
  • Start Date
    08/29/2018
  • End Date
    07/31/2019

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/15/2021
  • Study HIC
    #2000021141